Index

A
Abasaglar, 226
Abatacept, 500
Abbreviated Biologic License Application (aBLA), 76
Abbreviated new drug application (ANDA), 7
Abbreviated new drug submission (ANDS) pathway, 139
AbbVie, 28
ABP501, 294
on adalimumab PK profile, 593–594
analytical similarity, 592
clinical evidence, 593
of efficacy, 594–595
functional similarity, 592
immunogenicity, 595–596
inflammatory bowel disease, 592
PK similarity study, 593
safety, 596
ABP-501, 386
Abseamed, 226
Absolute neutrophil count (ANC), 132
Accofil, 226
Accountable Care Organizations (ACOs), 40
Active pharmaceutical ingredient (API), 225
Adalimumab, 498–499, 514–517, 654, see also ABP501
Adaptive analytical characterization strategy
adaptive characterization strategy, 313
biosimilar product characterization, 311–313
FDA regulatory guidelines, 306
lifecycle management
continued procedure performance verification, 315
FDA process validation guidance, 314
glycosylation, 314
ICH Q2(R1), 314
ICH Q8 (2009c), 314
monoclonal antibody biosimilar products, 316–318
procedure design, 315
procedure performance qualification, 315
QbD, 314
reference and biosimilar products, 314
protein product characterization, 307–309
reference product characterization, 309–311
351(k) licensure pathway, 306
Addressing assay variability
assay training, 414
assay troubleshooting, 415
cell type/cell line selection, 412–413
data analysis, 414
procedural accuracy, 413–414
Adverse drug reactions (ADR), 133
Affordable Care Act, 688
Agência Nacional de Vigilância Sanitária (ANVISA), 5
Agila Biotech Pvt. Ltd., 658
AlphaLISA, 396
Alpheon, 227
ambr®, 177, 178
Amgen, 27, 34–35, 93, 96
Amgen Inc. v. Hospira, Inc., 94–95
Amgen v. Apotex, 34–35
Amgen v. Hospira, supra, 98
Amgevita, 227
Amjevita®, 240

© American Association of Pharmaceutical Scientists 2018
H. J. Gutka et al. (eds.), Biosimilars, AAPS Advances in the Pharmaceutical Sciences Series 34, https://doi.org/10.1007/978-3-319-99680-6

693
Amjevita syringes, 244
Analysis of the variance (ANOVA), 562, 563
Analytical development
QbD and, 212
analytical method capability and continual improvement, 214
CMA, 212–213
control strategy, 213–214
design space, 213
QTAMP, 212
risk assessments, 213
Analytical methods, 213, 214
Analytical similarity
adjustment for age differences, 442–445
assessment, 434–435
biotechnology-derived drugs, 432
CQA
selection of K for Tier 2, 447–451
Tier 1 equivalence margin, 445–447
Tier 1 equivalence test, 438–441
description, 473–474
EMA statistical approach, 435–437
FDA approach, criticisms of (see FDA approach, criticisms of)
FDA statistical approach, 437–438
reference product, 433
stepwise approach, 433–434
test product, 433
Tier 2 testing, 441–442
Tier 3 testing, 445
Analytical similarity assessment
analytical testing plan
gold standards, 282
head-to-head testing, 284
intrinsic variability, 281
method qualification, 282
method suitability parameter selection, 283
method validation, 282
resolving power, 281
sensitivity of detection, 281
state-of-the-art analytical technologies, 281
biosimilar product, 274–275
data assessment
acceptable difference, 285
core fucosylation of N-glycans, 285
EMA, 288–290
Fcy3A receptor binding affinity, 285
U.S. FDA, 286–288
EMA guidelines, 262
forced degradation
ABP 501’s aggregation rate, 294
analytical method screening and selection, 292
analytical response measures, 296
CCD, 296, 297
comparative stress studies, 291, 299–301
contour plot, 297, 298
control samples, 297
experimental noise, 298, 299
generic experimental conditions, 291
head-to-head characterization tests, 291
LC-MS analysis, 295
product’s development lifecycle, 290
response measure, 295
selection of screening factors, 294
side-by-side analysis, 291
simultaneous analysis, 295
stressed materials, 291
test materials, 292–293
two-staged approach, 292
quality attribute, selection and ranking of assessment hierarchy, 280
criticality assessment, 277–278
definition, 275
degree of variability, 278
host cell proteins, 280
information sources, 278
molecular variants, 280
product-related substances/impurities, 278
qualitative vs. quantitative, 278–279
selection of, 276–277
Tool 1, 280
worst-case situation, 280
reference product
batch size, 268
comparator product, 268
legislative provisions, 268
Monte Carlo simulation, 269
non-domestic reference product, 268
obvious factor of risk, 268
spacing reference product procurement, 268
statistical analysis, 269
Tier 1 and Tier 2 assessments, 270–272
Tier 2 assessments, 272
test materials
analytical feasibility, 266–267
different presentations, 263–264
EU guideline, 263
incremental variability, 263
process changes, 262
product age, 264–266
statistical considerations, 267
| Analytical strategy, CMC, 182–185 |
| Anaphylaxis, 367 |
| Anion exchange (AEX) column purification, 346 |
| Antibody dependent cell cytotoxicity (ADCC), 605 |
| Antibody-dependent cell-mediated cytotoxicity (ADCC) assay, 401, 402, 414, 419 |
| Antibody-dependent cellular cytotoxicity (ADCC), 224 |
| Antibody dependent cellular phagocytosis (ADCP), 401 |
| Antibody drug conjugates (ADCs), 401 |
| Antibody therapeutics binding assays CLB, 396–397 LBA, 396 |
| bioassays in vitro cell line based bioassays, 398 in vitro tissue based bioassays, 398 in vivo bioassay, 397–398 reporter gene based bioassays, 398–399 |
| Anti-CD20 monoclonal antibody, 123 |
| Anti-drug antibodies (ADAs), 135, 136, 366 European perspective, on biosimilars, 159–161 |
| QbD, 203 |
| Anti-receptorMAbs, 400 |
| Anti-r-HuEpo, 678 |
| Apoptosis assay, 422 |
| Apotex, 34–35 |
| Aranesp®, 264 |
| Assay development, 136 |
| Assay repeatability, 405 |
| Assay troubleshooting, 415 |
| Association for Accessible Medicines (AAM), 4 |
| Avastin®, 241 |
| Average sales price (ASP), 55–57 |
| Avonex®, 367 |
| Biocon, 36, 658 |
| Biocopy, 677 |
| Biograstim, 228 |
Biological activity assays (cont.)
  potency assays, 395, 409–410
Reference Standard, 410–411
regulatory pathway, 408
robust analytical testing, 408
therapeutic MoA
  ADCs, 401
agonistic MoA, 399
antagonistic MoA, 399–400
effect function of MAbs, 401
multiple/novel MoA, 400–401
Biological medicines, 107
drug development, 108
Biological Price Competition and Innovation Act of 2009 (BPCIA), 30, 114
Biologicals Working Party (BWP), 146, 147
Biologic medicines, 123
Biologics, 7, 38, 43, 123, 222
R&D costs, 24–26
Biologics license application (BLA), 8, 115, 572
Biologics market, 16
Biologics Price Competition and Innovation Act (BPCI Act), 8, 10, 76–77, 471
biosimilar’s inaction, 83
biosimilar’s response, 80
commercialization, 180-day notice of, 83
confidential information, biosimilar’s disclosure of, 79
confidentiality provisions, 78–79
exchanged lists, 81–82
Hatch-Waxman Act, 84
infringement, act of, 78
litigation, preparation for
  biosimilar’s preparation, 89–90
  sponsor’s preparation, 86–88
negotiated list, 81
patent exchange/patent dance time line, 82
sponsor’s initial patent list, 80
sponsor’s reply, 81
Biologics Pricing Competition and Innovation Act (BPCI) Act, 544
Biologics Working Party (BWP), 9
Biopharma industry, 25
Biosimilar biologic drug approvals
authorizing indications, 137–138
Canadian guidance, 137
patent hold, 138–139
safety and efficacy, 137–138
biologics, 123–124
biotechnological/biologic products, comparability of, 124–125
clinical development, 130
efficacy, 133–135
immunogenicity, 135–137
pharmacodynamic studies, 132–133
pharmacokinetic studies, 130–132
safety, 133
development paradigm, 128–129
generic pharmaceuticals, 124
interchangeability, 139–141
non-clinical development, 130
post-market monitoring, 142
reference biologic drug, 126–128
regulatory framework, 125–127
switching, 141–142
Biosimilar development
  bridging studies, 119–120
  chemistry, manufacturing, and controls, 116–117
  clinical studies, 117–119
  global regulatory strategy framework, 108, 109
  interest/competitive intelligence, countries of, 108–110
  nonclinical studies, 117
  product target profile, 110
  regulatory pathways, 110
  EMA guidelines, 111–112
  FDA guidelines, 112–115
  WHO, 115–116
  regulatory strategy, 120
  strategic plan, 120
Biosimilar, evaluation process, 472–473
Biosimilar mAb HOS comparability analysis, 343–344
Biosimilar market, 23–24
  approvals, FDA lag in, 29
  barriers to entry, 26–29
  biologics R&D costs, 24–26
  biologics and, 43
  competition, 24
  data and market exclusivity, 30–31
  interchangeability, 37
  Mylan, 36
  patent dance, litigation
  Amgen v. Apotex, 34–35
  Janssen v. Celltrion, 35–36
  Sandoz v. Amgen, 32–34
  patents
    as barriers to entry, 31–32
    issues, 37
    litigation before application, 32
    patents and exclusivity, economic justification for, 29–30
potential gains, 41–42
pricing and market opportunities, 38–39
risks and return on investment, 42–43
in U.S., 39–41
Biosimilar Medicinal Products Working Party (BMWP), 9
Biosimilar Medicines Working Party (BMWP), 146
Biosimilar products, 394
Biosimilar r-HuEpo, 681
Biosimilars
AAM, 4
biologics market, 16
development and regulatory pathway
small vs. large molecules, 6–7
totality of the evidence, 8–9
U.S., small vs. large molecules, 7–8
drug development, evolution in, 4
Hatch-Waxman Act, 4
regulation
controversial regulatory concepts, 10
extrapolation, 10–12
harmonization, issue of, 15
history of, 9–10
switching vs. interchangeability, 12–15
reimbursement strategies and incentives, 18–19
TCSSDD, 4
tenets of, 5–6
uptake successes, 17–18
U.S. FDA, 5
Biosimilars drug products, 274–275
amjevita PFS, 250
API, 225
assessing similarity, 222
assessment considerations, 224–225
autoinjector, 251
BDP, 247
biobetter, 246
characterization, 311–313
container/closure system, 223
cyltezo PFS, 250
difference selected formulation, 245
different pH, 243
dosage forms for, 246–247
drug product manufacturing process, 251–252
enbrel PFS, 250
EU approved/refused and withdrawn products, 225–237
formulation, 223
herceptin, 244
“highly similar” molecule, 222
home-use products, 223
immunogenicity, 222
intellectual property, 223
in-use studies, consideration of, 245
life-cycle management
assay replacement/comparability, 406–407
binding or cell-based functional assays, 402
cell based assay optimization, 403–404
critical reagents, 406
legacy potency assay, 406–407
locked down, 402
method remediation, 403–404
method tech transfer, 408
method validation, 404–405
QTPP, 402
manufacturing process, 223
molecule and drug substance, 223–224
natural isotope abundance 2D NMR, 243
non-clinical and clinical safety, 222
PFS, 249
pharmacodynamics and pharmacokinetics, 222
primary packaging and device, 247–248
Pure Red Cell Aplasia, 250
quality parameters, 245
rubber components, 248–249
shelf-life, 244
silicone oil and tungsten, 249
structural stabilizers, 244
surfactants, 244
target concentration, 247
tier 1 equivalence test, 249
tier 3 qualitative comparison, 249
tier 2 quality range criteria, 249
tungsten pins, 250
type 1 glass, 248
US approved products, 225, 238–242
Biosimilars, in India development and commercialization
analytical similarity
filgrastim, 665–667
G-CSF, 654
ICH Q5E and Q6B guidelines, 664
independent in-depth similarity, 665
rituximab biosimilars, 667–669
biosimilar confirmatory, 654–655
biosimilars regulations
CDSCO, 659–660
EMA, 659
key stakeholders, 660
KFDA, 659
MFDS, 659
Biosimilars, in India development and commercialization (cont.)
2016 guidelines, 661–664
US-FDA, 659
WHO, 659
CAGR, 654
clinical similarity, 669–670
Filgrastim, 654
global biosimilar market, 656–657
Indian biosimilar market, 657–658
Indian biotech sector’s revenue, 654
Indian players with global partnerships, 658
insulin analogs, 654
monoclonal antibodies, 654
prices of biologics, 656
scientific bridge, 654
small molecule generics vs. biosimilars, 655
Biosimilar sponsor’s testing, 417
Blitzima, 228
B-lymphocytes, 491
Broader reasonable interpretation, 101
Bulk drug product (BDP), 247
C
Canada, biosimilar biologic drug, see Biosimilar biologic drug approvals
Canadian reference product (CRP), 139
Capable process, 210
Cation-exchange chromatography, 179
Cation exchange (CEX) column purification, 346
CD spectroscopy, 331
Cell-based binding assays (CBA), 396
Cell surface antigen binding assay, 422–424
Celltrion, 35–36, 93, 94
Celltrion’s follow-up data package, 591–592
Center for Medicare and Medicaid Innovation (CMMI), 71
Centers for Medicare and Medicaid Services (CMS), 51, 54
Central composite design (CCD), 296, 297
Central Drug Standard Control Organization (CDSCO), 657
Certificate of Analysis, 174
Chaperone proteins, 352
Chemistry, manufacturing and controls (CMC), 173
BDS, specifications for, 181
expression systems and clonal selection, 175–177
implementation and analytical strategy, 182–185
product quality and control strategy, manufacturing conditions on, 180–182
raw materials effect, 179–180
reference drug, 174–175
upstream and downstream processes and scale-up to manufacturing, 177–179
Cipla Ltd., 657, 658
Circular dichroism (CD), 331, 340
Clinical Commissioning Groups (CCGs), 18, 67
Clinical development
biosimilar biologic drug approvals, 130
efficacy, 133–135
immunogenicity, 135–137
pharmacodynamic studies, 132–133
pharmacokinetic studies, 130–132
safety, 133
Clinical studies
European perspective, biosimilars, 155
clinical comparability, 158–159
extrapolation of efficacy and safety, 162–163
immunogenicity, 159–161
interchangeability, 163–165
pharmacodynamic comparability, 157–158
pharmacokinetic comparability, 155–157
Clinical trial materials (CTM), 189
Clonal selection, CMC, 175–177
Commercialization, 180-Day Notice of, 89
Committee for Human Medicinal Products (CHMP), 146, 147
Committee for Medicinal Products for Human Use (CHMP), 9
Comparative clinical studies, design considerations
bevacizumab, 480–483
clinically meaningful differences, 475–477
etanercept, 478–479
filgrastim, 479–480
safety signals, 477–478
stepwise approach, 474
Competitive intelligence, countries of, 108–110
Competitive ligand binding (CLB) assay, 396–397, 400
Complement-dependent cytotoxicity (CDC) assay, 402, 414, 419–422
“Composition of matter” patent, 31
Compound annual growth rate (CAGR), 654
Confirmatory phase III-type safety, 619–620
Consumer Price Index-Urban (CPI-U) adjustment, 62
Continual improvement, 196, 214
Control strategy, QbD, 195–196
Conventional cleanroom, 253
Corynebacteria, 175
Coverage gap, 58
Coverage Gap Discount Program (CGDP), 58
C1q binding assay, 425
Critical formulation attributes (CFAs), 215
Critical material attributes (CMAs), 190
Critical process parameters (CPP), 194
Critical quality attributes (CQAs), 129, 174, 175, 180, 182–185, 366, 688
QbD, 191–192, 200–201
selection of K for Tier 2, 447–451
Tier 1 equivalence margin, 445–447
Tier 1 equivalence test, 438–441
CT-P13 in afucosylated species, 585–586
analytical characterization, 582–583
Celltrion’s follow-up data package, 591–592
clinical development program, 587
efficacy and safety comparison, 587–588
functional characterization, 582–583
AS patients, PK equivalence study, 584, 587
RA and AS indicators, 589–591
residual uncertainty of afucosylated glycans, 583–584
Cyltezo™, 228, 241, 246
Cyltezo syringes, 244

D
Darbepoetin, 499–500
DasBox, 177
Decision rules, 287
Design of Experiments (DOE) approach, 193–194, 207–208
Design space
QbD, 193–195
QTPP, 207–209
Differential scanning calorimetry (DSC), 332
District Level Committee (DLC), 660
DM Corporation, 658
Donut hole, 58
Draft Reflection Paper, 289, 290
Dr. Reddy’s Laboratories, 657
Drug Controller General of India (DCGI), 660
Drug product (DP), 189
Drug substance (DS), 189
Dynamic light scattering (DLS), 378–380

E
ELISA-based assay, 352
ELISA-based binding assay, 344
ELISA-based method, 343
Enbrel®, 27, 239
Enbrel PFS, 250
Endogenous proteins, 491
Enzyme linked immuno-sorbent assay (ELISA), 396
Epoetin alfa-ADAs, 159
Epoetin Alfa Hexal, 229
Epoetin Hospira, 688
Epogen®, 93, 687
Epogen/Procrit, 242
Eprex®, 683, 687
Erelzi®, 229, 239, 246
Erelzi® methods, 614
Erythropoiesis-stimulating agent (ESA), 387
Erythropoietin (EPO), 16
Etanercept®, 17, 96, 353, 478–479
EudraVigilance, 643
European Crohn’s and Colitis Organization (ECCO), 11
European Economic Area (EEA), 151
European Medicines Agency (EMA), 5, 6, 111–112, 128, 262, 288–290, 659, 680
guidelines and scientific assessment reports, 146
European Medicines Evaluation Agency (EMEA), 146
European perspective on biosimilars assessment of biosimilars, 149–150
clinical studies, 155
clinical comparability, 158–159
extrapolation of efficacy and safety, 162–163
immunogenicity, 159–161
interchangeability, 163–165
pharmacodynamic comparability, 157–158
pharmacokinetic comparability, 155–157
EU, 146
evolution of, 147
guidelines, for biosimilars, 148–149
non–clinical development, 153–155
European perspective on biosimilars (cont.)
post-marketing surveillance, 167
product information, 165–166
quality, 151–153
reference product, 151
European Pharmacopeia (EP), 200
European Union (EU), 146
evolution of, 147
Expression systems
CMC, 175–177
Extrapolation
ABP501
on adalimumab PK profile, 593–594
analytical similarity, 592–593
clinical evidence, 593
of efficacy, 594–595
functional similarity, 592–593
immunogenicity, 595–596
inflammatory bowel disease, 592
PK similarity study, 593
safety, 596
biosimilar biologic drug approvals,
137–138
Canadian guidance, 137
patent hold, 138–139
safety and efficacy, 137–138
biosimilars, regulation, 10–12
BLA pathway, 572
CT-P13
in afucosylated species, 585–586
analytical characterization, 582–583
Celltrion’s follow-up data package,
591–592
clinical development program, 587
efficacy and safety comparison,
587–588
functional characterization, 582–583
AS patients, PK equivalence study, 584,
587
RA and AS indications, 589–591
residual uncertainty of afucosylated
glycans, 583–584
European perspective on biosimilars,
162–163
immunogenicity comparisons, 580–581
MOAs
antibody drugs, 576–577
drug delivery carriers, 577
efficacy and safety, 578–579
glycosylation impacts, 577
hormonal protein drugs, 576
structural residual uncertainty, 577–578
modeling and simulation, potential,
581–582
PK considerations, 579–580
regulatory requirement
EMA, 575
FDA, 574
Health Canada, 575–576
scientific principles, 573
TMDD, 581
Totality of Evidence, 621
Extrinsic particles, 365

F
Fcγ R I binding assay, 425
Fcγ R IIb binding assay, 425–426
Fcγ RIIa-Phe binding assay, 427
Fcγ R IIIa-Val binding assay, 427
FcRn binding assay, 427–428
FDA approach, criticisms of
correlation effects, 460–465
reformulation of hypotheses, Tier 1 test
equal variances, 456–457
numerical data, 458–459
simulated type I error rates, 459–460
unequal variances, 457–458
Tier 1 test
impact of correlation, 453–454
inflation of type I error, 452–453
Tier 2 test
impact of correlation, 455
selection of K, 454–455
Federal Food, Drug, and Cosmetic Act (FD&C
Act), 112
Federal Medical Assistant Percentage (FMAP),
61–62
Fee-for-service (FFS) model, 70
Filgrastim, 200, 479–480
Filgrastim hexal, 229
Filgrastim ratiopharm, 229
Fingerprint-like similarity, 312, 328–330
Flixabi, 230
Flow imaging microscopy (FIM) analysis,
376–377
Food and Drug Administration (FDA)
guidelines, 112–115, 128
immunogenicity assessment, therapeutic
indications, 513
protein particulates
additional particle detection, 369
Amgen’s submission, 370
antigenic proteins, 368
light obscuration analysis, 370, 375
particle characterization methods, 370
safety and efficacy, 369
similarity assessment, 371–374
Index

... totality of evidence, 370
USP 788, 369
USP 1787, 369
Food and Drug Regulations, 125
Food and Drugs Act, 125
Food and Drugs Control Administration (FDCA), 660
Formulation development QbD and, 214–215
CFAs, 215
control strategy, 216
design space, 216
formulation capability and continual improvement, 216–217
prior knowledge, 217
risk assessments, 216
Fortical, 113
Fourier transform infrared (FTIR) spectroscopy, 331–332, 352
4PL model, 417
FTIR spectroscopy, 324
Fulphila, 242
Functional assays, 153, 181

G
Generic/automatic substitution, 139
Genetic Engineering Approval Committee (GEAC), 660
Global biosimilar market, 656–657
Glycosylated molecules, 180
Glycosylation, 174, 176, 314
GMP compliant software package, 417
Good manufacturing practices (GMP), 26
Good manufacturing processes (GMP), 684
Granulocyte colony stimulating factor (G-CSF), 664
Grastofil, 230

H
Harmonization of biosimilars, 15
Hatch-Waxman Act, 4, 85
Health Canada, 126, 128, 130, 132, 138, 142
Healthcare Common Procedure Coding System (HCPCS), 51
Herceptin®, 241
Herceptin (Trastuzumab), 343
Herceptin vial, 247
Higher order structure (HOS) methods, 340
current industry landscape, 322–324
FDA and EMA guidance, 322
industry perception, 324–326
method strategy
circular dichroism, 331
1-D NMR, 332–333
2-D NMR, 333
DSC, 332
FTIR spectroscopy, 331–332
HDX, 333
intrinsic fluorescence, 334
qualifying HOS methods, 330
UV CD, 330
X-ray crystallography, 334
polymorphism (see HOS polymorphism)
selection considerations
fingerprint-like similarity, 328–330
FTIR spectroscopy, 326
hypothetical relationship, 327, 329
method capabilities, 326
risk assessment models, 326
risk mitigation, 326
spectroscopic methods, 326
value and cost, 327, 328
High performance size-exclusion chromatography (HP-SEC), 685
Hospira, 93
HOS polymorphism
chaperone proteins, 352
four different molecules, 355
mAb HOS stability, 352
8M urea-treated sample, 353
PCA technology
chaperone proteins, 352
four different molecules, 355
mAb HOS stability, 352
8M urea-treated sample, 353
refolding process, 354
serum-derived human IgG, 353	hree different molecules, 354
refolding process, 354
serum-derived human IgG, 353	hree different molecules, 354
Host-cell DNA (HCDNA), 174
Host-cell proteins (HCP), 174, 685
Human gamma globulin (HGG), 366
Human MHC Class II proteins, 491
Human serum albumin (HSA), 367, 684
Humira®, 240, 250, 380, see also ABP499
Humira (Adalimumab), 344
Hydenex, 113
Ich Q8(R2), 306

Immune system, 159–161

Immunoex, 96

Immunex Corp. v. Sandoz, Inc., 92

Immunogenicity, 162, 222

- clinical development, 135–137
- European perspective, biosimilars, 159–161

Immunogenicity assessment

- acceptable differences
  - conditions, 507
  - etanercept, 510–512
  - FDA guidance, 506
  - infliximab, 507–510
  - rituximab, 512–513

- cell-mediated, 490
- clinical evidence, 530
- confounding patient-related variables, control of, 518–519
- EU and FDA guidance, 495
- evaluation parameters
  - efficacy, 504–505
  - immune response parameters, 500–503
  - PK and PD parameters, 504
  - safety, 505–506

- humoral elements, 490
- immunogenic biosimilar candidates, 532
- individual product quality attributes, 531
- infliximab biosimilar, 517
- in vitro assays, 531
- mitigation of risk, 493–494
- multi-disciplinary exercise, 490
- non-clinical evaluation, 494–495
- post-authorization risk mitigation
  - control of risks, originator products, 527–528
  - independent post-authorization
    - life-cycles, uncertainty, 529–530
  - precision profiling, 531
- product quality variables, 492–493
- reference product, risk profile for
  - abatacept, 500
  - adalimumab, 498–499
  - darbepoeitin, 499–500
  - immunogenicity-related risks, 496
  - pegfilgrastim, 497–498
- risk-based approach, 490
- rituximab biosimilars, 517
- switching and interchangeability
  - biosimilarity, 519–520
  - caution, 523
  - DANBIO registry, 523
  - EU and US meaning, 519
  - experts expressing opinions, 524
  - NOR-SWITCH phase 4 trial, 522
  - PLANETAS study, 520–521
  - PLANETRA study, 521–522
  - retrospective cohort study, 523
  - rheumatoid arthritis patients, 523
  - in US, 524–527
  - therapeutic indications
    - adalimumab, 514–517
    - EU guidance, 514
    - FDA guidance, 513
  - therapeutic proteins, 491–492

- Immunogenicity package, 161
- Immunogenicity testing, 118, 137
- Imraldi, 230
- Inbiopro Solutions Pvt. Ltd., 658
- Indication-specific assays, 153
- Industry M4Q, 306
- Inflammatory bowel disease (IBD), 11–12, 162
- Inflectra®, 230, 238, 244
- Infliximab, 11, 69, 136, 141, 153, 162
  - 507–510, see CT-P13
- Inherent particles, 365
- Inhiba, 231
- Inst., Inc. v. Iancu, 101
- Institute for Clinical Effectiveness and Research (ICER), 71
- Institutional Animal Ethics Committee (IAEC), 660
- Institutional Biosafety Committee (IBSC), 660
- Intas Biopharmaceuticals, 658
- Intellectual property, 223
- Interchangeability, 12–15, 118, 519
  - biosimilar biologic drug approvals, 139–141
  - biosimilar market, 37
  - European perspective on biosimilars, 163–165
  - stepwise approach, 483–484

- Interchangeability study design and analysis
  - adverse events, 563
  - analysis of the variance, 562, 563
  - BPCI Act, 544
  - calendar time, 570
  - data analysis, 561–563
  - drug supply, 565–566
  - in European Union, 545–546
  - FDA guidance, 545
  - modeling approach, 566–567
  - number of cycles, estimation, 570
  - regulatory approach, 544
  - switching and substitution, 545

Index
switching study
CV estimation, 554–557
dropout rate, 557–560
duration, 550
endpoints, 547
immunogenicity sampling and PK, 550
lead-in period, 548–550
patient population, 561
PK sampling period, 547
sample size, 551–554
serum drug concentration, 549
stratification, 561
Weibull model, 559
in United States, 546
in worldwide, 546
Interest/competitive intelligence, countries of, 108–110
International Council on Harmonization (ICH), 125, 128
International Nonproprietary Name (INN), 167
Inter partes review (IPR), 98–99
estoppel, 102
legal standards, 100–101
patent owners, 103–104
petitioners, 103
petition for, 99
statistics, 102–103
timeline for, 100
Intravenous immunoglobulin (IVIG), 679
Intrinsic fluorescence, 334, 352
Intrinsic particles, 365
In vitro cell line based bioassays, 398
In vitro tissue based bioassays, 398
In vivo bioassay, 397–398
IPCA Laboratories, 658
Ixifi™, 239, 244

J
Janssen, 35–36, 93, 94
Janssen Biotech Inc. v. Celltrion Healthcare Co., 96
Janssen v. Celltrion, 97
J-code policy, 51
stakeholder considerations on, 54–56
Johnson & Johnson, 28, 217
Juvenile idiopathic arthritis (JIA), 246

K
Korean Food and Drug Administration (KFDA), 659
Korea’s Ministry of Food and Drug Safety (MFDS), 659

L
Ligand binding assay (LBA), 396
Light microscopy, 383
Light obscuration (LO), 370, 375
Lipitor, 41
Litigation-related issues
Amgen Inc. v. Hospira, Inc., 94–95
ANDA, 76
biosimilar product types/naming, 77–78
BPCIA, 76–77
biosimilar’s inaction, 83
biosimilar’s response, 80
commercialization, 180-day notice of, 83
confidential information, biosimilar’s disclosure of, 79
certainty provisions, 78–79
exchanged lists, 81–82
 Hatch-Waxman Act, 84
infringement, act of, 78
negotiated list, 81
patent exchange/patent dance time line, 82
sponsor’s initial patent list, 80
sponsor’s reply, 81
BPCIA litigation, preparation for
biosimilar’s preparation, 89–90
sponsor’s preparation, 86–88
Hatch-Waxman safe harbor, 84–86
Immunex Corp. v. Sandoz, Inc., 92–93
information, confidential exchange provision, 95–98
IPRs, 98–99
estoppel, 102
legal standards, 100–101
patent owners, 103–104
petitioners, 103
petition for, 99
statistics, 102–103
timeline for, 100
patent dance mandatory, 90–92
Luminex-based multiplex assay, 352
Luminex multiplex system, 357–359
Luminex xMAP®Multiplex Technology Platform, 352
Luminex xMAP technology, 355–357
Lupin Ltd., 658
Lusduna, 231

M
mAb biosimilarity analysis, 343–344
mAb glycosylation, 351
Managed Care Organizations (MCOs), 62–63
Mannose, 224
Marketing authorisation (MA) process, 149–150
Marketing Authorization Application (MAA), 112
Mechanism of actions (MOAs), 119, 396
antibody drugs, 576–577
drug delivery carriers, 577
efficacy and safety, 578–579
glycosylation impacts, 577
hormonal protein drugs, 576
structural residual uncertainty, 577–578
Medicaid
CPI-U adjustment, 62
FMAP, 61–62
MCOs, 62–63
MDRP, 62
PDLs, 62
physician-administered drugs, coverage and payment for, 63
Medicaid Best Price, 62
Medicaid Drug Rebate Program (MDRP), 62
Medicare, 52
blended J-code policy, stakeholder considerations on, 54–56
coding and payment policy, 56–58
Medicare Part B, 53–54
Medicare Part D, 58–61
Medicare Administrative Contractors (MACs), 53
Medicare Modernization Act (MMA), 56
Medicare Part B
coding, 53–54
coverage, 53
Medicare Part D
biosimilars impact, 59–61
CGDP, 58
coverage gap, 59
donut hole, 58
Medicare Physician Fee Schedule (MPFS), 54
Method capabilities, 326
Microfluidic resistive pulse sensing (MRPS), 385–386
Ministry for Health Labour and Welfare (MHLW), 659
Monoclonal antibodies (mAbs), 340, 394
binding, 399
Monoclonal antibody, QbD, 197–199, 204–205
Monte Carlo simulations, 269, 288
Morphology-directed Raman spectroscopy (MDRS), 383–385
Movymia, 231
Mvasi™, 231, 241
Mylan, 36, 223

N
N-acetyl neuraminic acid (NANA), 179
Nanoparticle tracking analysis (NTA), 380–381
National Drug Codes (NDCs), 51
National Health Service (NHS), 17–18
National Institute of Health and Care Excellence (NICE), 68
National regulatory agencies (NCAs), 146
Neulasta, 242
Neupogen®, 238
New Drug Application (NDA), 7
Nivestim, 232
Non–clinical development
biosimilar biologic drug approvals, 130
European perspective, on biosimilars, 153–155
Non-clinical testing, 117
Non-Hodgkin’s lymphoma (NHL), 123
Nonmedical switching, 12
NOR-SWITCH study, 13
Norwegian Drug Procurement Cooperation, 17, 69
Notice of Compliance (NOC), 139

O
Office of Patented Medicines and Liaison (OPML), 138
Ogivri™, 241
Omnitrope, 113, 232
1-D NMR, 324, 332–333
One Factor At a Time (OFAT) studies, 193, 208
Ontruzant, 232
Optical microscopy, 383
Orthogonal method, 324
Ovaleap, 232
Overall survival (OS), 134

P
Patent dance, litigation
biosimilar market
Amen v. Apotex, 34–35
Janssen v. Celltrion, 35–36
Sandoc v. Amgen, 32–34
litigation-related issues, 90–92
Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations), 138
Patent Statute, 77
Patent Trial and Appeal Board (PTAB), 99, 102
Patient acceptance, 65
Pediatric Study Plan (PSP), 119
Pegfilgrastim, 497–498
PEGfilgrastim biosimilar, 27
Peginesatide®, 387
PEGylated proteins, 368
Peripheral blood mononucleated cells (PBMCs), 412
Peroxides, 179
Pfizer, 28, 38
Pharmaceutical and Medical Devices Agency (PMDA), 5
Pharmacodynamic studies, clinical development, 132–133
Pharmacokinetic studies, clinical development, 130–132
Pharmacopoeia, 283
Pharmacovigilance adverse drug reactions, 633–634
AEs/risks associated with drugs in EU, 642–643
in Japan, 643–644
in South Korea, 644
in Taiwan, 644
in Thailand, 644–645
in US, 641–642
areas of medicine, 645
causality analysis, 639
communication of risk, 639
EudraVigilance, 643
importance of, 634–635
medication errors, 634
multisource biologics market, 635–637
product quality, 633
risk determination, 639
signal detection, 637–638
unique identifiers, 640–641
World Health Organization, 645
Pharmacy benefit managers (PBMs), 64
Phosphate buffered saline, 215
Physicochemical analyses, 394
PLANETAS study, 520–521
PLANETRA study, 521–522
PNS Pharma, 42
Polysorbates, 179
Post-market monitoring biosimilar biologic drug approvals, 142
Post-translational modifications (PTMs), 128, 174–176
Potency assays, 395, 409–410
Potential risk, 533
Preferred Drug Lists (PDLs), 62
Prefilled syringes (PFS), 249
Prior knowledge, 196, 211–212, 214
Process analytical technology (PAT), 195
Process characterization, 193
Process patent, 31
Process performance qualification (PPQ), 193
Productivity, 176
Product quality attribute assessment (PQAA), 313
Product target profile, 110
Protein A, 174
Protein attribute-process risk classification, 310
Protein-based pharmaceutical products, 306
Protein conformational array (PCA) technology bioprocess development Biosimilar-1 drug substance, 347
CEX and AEX column purification, 346
full panel HOS analysis of, 347, 348
heavy chain CH3 amino acid 355–379, 345
HOS analysis of, 346
‘mAb heavy chain amino acid 154–179’, 345
PCA ELISA, 345
CD, 340
design diagram, 341
development, 341–342
“fingerprint-like” technology, 340
fluorescence spectroscopies, 340
formulation development HOS analysis of, 348–351
IgG2 sample, 348
IgG2 vs. IgG1 molecule, 349
light exposure, 351
mAb glycosylation, 351
mAb HOS stability, 348
MAb stability, 348
N-glycosylation, 352
PCA ELISA, 348
V_L and C_L domains (pAb6), 349
FTIR, 340
HOS polymorphism chaperone proteins, 352
four different molecules, 355
mAb HOS stability, 352
8M urea-treated sample, 353
refolding process, 354
serum-derived human IgG, 353
three different molecules, 354
immunology epitope scanning principle, 340
Luminex multiplex system, 357–359
Luminex xMAP technology, 355–357
Protein conformational array (PCA) technology (cont.)
- mAb biosimilarity analysis, 343–344
- mAb HOS, 340
- magnetic beads-based Luminex format, 340
- microplate-based ELISA format, 340

Protein particulates
- ABP-501, 386
- anaphylaxis, 367
- biological consequence of immunogenicity, 367
- degradation processes, 364
- extrinsic, intrinsic and inherent, 365

FDA guidance
- additional particle detection, 369
- Amgen’s submission, 370
- antigenic proteins, 368
- light obscuration analysis, 370, 375
- particle characterization methods, 370
- safety and efficacy, 369
- similarity assessment, 371–374
- totality of evidence, 370
- USP 788, 369
- USP 1787, 369

immunogenicity, 366–368
- injectable therapeutic protein, 364
- multiple orthogonal methods, 364
- novel technologies for
  - MDRS, 383–385
  - MRPS, 385–386
  - RMM, 382–383
- pure red cell aplasia, 367
- quantify and size protein aggregates, 364
- submicron particles
  - DLS, 378–380
  - NTA, 380–381
- subvisible particles
  - FIM, 376–377
  - LO, 370, 375, 376

Protein product characterization, 307–309
Proteomics analysis, 687
Public Health Service Act (PHS Act), 13, 76, 114
Pure red cell aplasia (PRCA), 677

Quality attributes and methods
- monoclonal antibodies, 610–613
- Zarxio® methods, 607–609

Quality by design (QbD), 314
- and analytical development, 212
- analytical method capability and continual improvement, 214
- CMA, 212–213
- control strategy, 213–214
- design space, 213
- QTAMP, 212
- risk assessments, 213
- application of, 188, 196–197
- control strategy, 209–211
- CQA development, 200–201
- CQAs, 200–202
- design space, 207–209
- QTPP, 197–199
- risk assessments, 201–207
  - control strategy, 195–196
  - CQA, 191–192
  - CTM, 189
  - definition, 189
  - design space, 193–195
  - elements of, 190
  - and formulation development, 214–215
  - CFAs, 215
  - control strategy, 216
  - design space, 216
  - formulation capability and continual improvement, 216–217
  - prior knowledge, 217
  - risk assessments, 216
- QTPP, 191
  - quality target product profile, 191
  - risk assessments, 192–193
- SISPQ, 189

  - control strategy, 209–211
  - CQAs, 200–202
  - design space, 207–209
  - risk assessments, 201–207

R
- Radio-immunoprecipitation test (RIP), 678
- Raman spectroscopy, 383–385
- Ranbaxy Laboratories Ltd., 658
- RAND Corporation, 16
- Ratiogristim, 233
- Rayleigh approximation, 380
rDNA technology, 148
Rebif®, 367
Recombinant DNA Advisory Committee (RDAC), 660
FDA approval, 606
high similarity, 604
implicit concept, 604
information support for Non US sources, 620–621
molecular characteristics, 606
non-clinical animal testing, 616–618
novel biopharmaceuticals, 602
product and manufacturing quality, 605
quality attributes and methods
  monoclonal antibodies, 610–613
  Zarxio® methods, 607–609
regulatory pathway vs biosimilar regulatory pathway, 603
valuable immunogenicity data, 619
Transmissible spongiform encephalopathies (TSE), 179
Trastuzumab, 286, 654
Truxima, 237
Tufts Center for the Study of Drug Development (TCSDD), 4
Tumor necrosis factor (TNF), 478
Tumour necrosis factor (TNF) biosimilar drugs, 69
Tungsten pins, 250
Tween®, 179
2-D NMR, 324
Two one sided tests (TOST), 476

U
United States Food and Drug Administration (U.S. FDA), 262, 286–288, 659, 687
United States Pharmacopeia (USP), 180
“Use” patent, 31
US pharmacopeia (USP) monograph, 369
UV CD spectroscopy, 324

V
Valtropin, 113, 237

W
Weighted spectral difference (WSD), 331
World Health Organization (WHO), 115–116, 659

X
X-ray crystallography, 324, 334

Z
Zarxio®, 28, 37, 40, 54, 238, 245, 607–609
Zarzio, 237
Z-ave, 378
Zydus Cadila, 657